Glaukos Corporation recently announced that its technologies were featured across scientific programming at the American Society of Cataract and Refractive Surgery annual meeting in Washington, D.C., ...

Epioxa from Glaukos is the first epithelium-on corneal cross-linking treatment that has been FDA approved in the United ...

Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

Please provide your email address to receive an email when new articles are posted on . In the world of technology, disruptors are sought-after and celebrated. When Roy S. Rubinfeld, MD, MA, led the ...

SHERBORN, Mass.--(BUSINESS WIRE)--CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, ...

Keratoconus is a rare, progressive ophthalmic disorder characterized by changes to the cornea that result in significant vision loss. Epioxa is an oxygen-enriched, UV-bioactivated topical treatment ...

Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal ...

Glaukos Corporation GKOS recently announced the commercial availability of Epioxa, marking a significant milestone in its corneal health portfolio. The therapy stands out as the first FDA-approved, ...

A pediatric subgroup from a pivotal phase 3 trial randomized 2:1 showed epithelium-on oxygen-enriched CXL improved Kmax at 6 ...

On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...